Peter F Thall

Jan 18, 2024 | nature.com | Hind Rafei |May Daher |Vakul Mohanty |Merve Dede |Peter F Thall |Roland Bassett | +6 more

AbstractThere is a pressing need for allogeneic chimeric antigen receptor (CAR)-immune cell therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord blood-derived natural killer (NK) cells expressing anti-CD19 chimeric antigen receptor and interleukin-15 (CAR19/IL-15) in 37 patients with CD19+ B cell malignancies. The primary objectives were safety and efficacy, defined as day 30 overall response (OR).